Bristol-Myers Squibb Company said the ongoing phase III CheckMate-227 study met its co-primary endpoint of progression-free survival with the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination versus chemotherapy in first-line advanced non-small cell lung cancer patients whose tumors have high (≥10 mutations/megabase, mut/mb) tumor mutation burden, regardless of PD-L1 expression.
“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.
